HitGen Partner BioAge Launches Phase II Trial for BGE-102
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
SAN DIEGO, Calif., July 14, 2026 Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and...
